Roche 3Q Sales Increase on Strong Performance of Recently Launched Drugs
October 19 2017 - 2:07AM
Dow Jones News
By Sonia Amaral Rohter
Roche Holding AG (ROG.EB) said on Thursday that third-quarter
sales increased 4.9% on continued strong sales of recently launched
drugs.
The Swiss health-care company reported third-quarter sales of
13.09 billion Swiss francs ($13.35 billion), compared with CHF12.48
billion a year earlier.
According to a Factset survey, analysts expected group sales for
the quarter of CHF13.12 billion.
Revenue at Roche's pharmaceuticals division, which accounts for
more than three-quarters of sales, increased to CHF10.12 billion,
from CHF9.68 billion a year earlier. Revenue in its diagnostics
division rose 6.1% to CHF2.98 billion.
Sales of three recently launched drugs, Ocrevus, Tecentriq and
Alecensa accounted for more than half of the pharmaceutical
division's growth.
The company confirmed its full-year outlook of mid-single-digit
sales growth at constant exchange rates, with earnings per share
expected to grow in line with sales. Roche said it continues to
expect further increases to its dividend.
"Based on the strong sales growth of our pharmaceuticals and
diagnostics divisions in the first nine months, I am confident that
we will achieve our full-year targets. The growth is largely driven
by new product launches," said Chief Executive Severin Schwan.
Write to Sonia Amaral Rohter at
sonia.amaralrohter@dowjones.com
(END) Dow Jones Newswires
October 19, 2017 01:52 ET (05:52 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Sep 2023 to Sep 2024